温性自己免疫性溶血性貧血（WAIHA）治療の世界市場レポート 2025年

温性自己免疫性溶血性貧血（WAIHA）治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.5％で8億7,000万米ドルに成長します。予測期間中の成長は、自己免疫疾患の有病率の上昇、ヘルスケア専門家の意識の向上、生物製剤や標的療法の採用拡大、自己免疫疾患の治療における適応外薬の使用増加などに起因すると考えられます。この期間に予想される主要動向には、モノクローナル抗体治療の進歩、診断における次世代シークエンシング（NGS）の統合、免疫学研究の進展、技術主導型創薬プラットフォームの利用などがあります。

ヘルスケア支出の増加は、今後数年間の温性自己免疫性溶血性貧血（WAIHA）治療市場の拡大を促進すると予想されます。ヘルスケア支出には、個人、政府、組織による予防、診断、治療、疾病管理などのヘルスケアサービスに費やされる総資源が含まれます。新しい診断ツールや治療法の開発、導入、継続的なケアには一般的に高いコストがかかるため、医療技術の開発がヘルスケア支出の増加に寄与しています。ヘルスケア支出は、研究に資金を提供し、先進的診断ツールへのアクセスを容易にし、病気を管理コントロールする専門的な治療法の利用可能性を確保することで、WAIHAの治療を支えています。例えば、2024年5月、英国の国家統計局は、2022年の実質的な医療社会保障費は2.8％増加し、2023年には医療費全体が5.6％増加したと報告しました。したがって、医療費の増加はWAIHA治療市場の成長を促進する重要な要因です。

モノクローナル抗体治療における技術革新は、温熱性自己免疫性溶血性貧血（WAIHA）治療の進歩を促進しており、市場の主要企業は、満たされていない臨床ニーズを満たし、患者の転帰を向上させる最先端のソリューションの開発に注力しています。モノクローナル抗体は、特定の免疫細胞や経路を標的とするように設計された実験室製のタンパク質であり、WAIHAにおける赤血球の破壊を抑えることを目的としています。例えば、2023年7月、中国に本社を置くバイオ医薬品会社であるIASO BIoTechnologyは、米国食品医薬品局（FDA）が、WAIHAや原発性免疫性血小板減少症（ITP）を含む自己免疫性血液疾患における臨床検査用として、IASO-782注射剤を米国で承認したと発表しました。この完全ヒト型モノクローナル抗体はCD19を標的とし、他のFc機能を維持しながらADCC活性を高めるためにFc変異を組み込みました。この抗体は、CD19+B細胞、血漿芽球、自己反応性抗体を産生する特定の血漿細胞を特異的に除去します。そのユニークなメカニズムにより、IASO-782は、ITPや自己免疫性溶血性貧血（AIHA）のような、病原性B細胞や形質細胞によって駆動される自己免疫疾患を治療する可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の温性自己免疫性溶血性貧血（WAIHA）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：成長率分析
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場の実績：規模と成長、2019～2024年
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• モノクローナル抗体
• 静脈内免疫グロブリン（IVIG）
• 輸血
• 脾臓摘出術
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 皮下
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：患者人口統計別、実績と予測、2019～2024年、2024～2029年、2034年
• 幼児
• 成人
• 高齢者
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：治癒領域別、実績と予測、2019～2024年、2024～2029年、2034年
• 原発性自己免疫疾患
• 二次性自己免疫疾患
• 遺伝的素因
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プレドニゾン
• デキサメタゾン
• メチルプレドニゾロン
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場、モノクローナル抗体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• リツキシマブ
• スティムリマブ
• ボルテゾミブ
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場、静脈内免疫グロブリン（IVIG）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 標準IVIG
• 高用量IVIG
• プール血漿由来免疫グロブリン
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場、輸血のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 白血球除去赤血球輸血
• 緊急輸血
• 表現型適合赤血球輸血
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場、脾臓摘出術のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 腹腔鏡下脾臓摘出術
• 脾臓摘出後の予防的治療
• 開胸脾臓摘出術

第7章 地域別・国別分析

• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の温性自己免疫性溶血性貧血（WAIHA）治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 温性自己免疫性溶血性貧血（WAIHA）治療市場：競合情勢
• 温性自己免疫性溶血性貧血（WAIHA）治療市場：企業プロファイル
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Novartis AG

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Agios Pharmaceuticals Inc.
• Incyte corporation
• Mallinckrodt Pharmaceuticals
• Hutchison Medipharma Limited
• BioCryst Pharmaceuticals Inc.
• Xencor Inc.
• Annexon Inc.
• Rigel Pharmaceuticals Inc.
• Apellis Pharmaceuticals Inc.
• Momenta Pharmaceuticals Inc.
• Immunovant Inc.
• Zenas BioPharma Inc.
• Alexion Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 温性自己免疫性溶血性貧血（WAIHA）治療市場、2029年：新たな機会を提供する国
• 温性自己免疫性溶血性貧血（WAIHA）治療市場、2029年：新たな機会を提供するセグメント
• 温性自己免疫性溶血性貧血（WAIHA）治療市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Treatment for warm autoimmune hemolytic anemia (WAIHA) centers on addressing the immune system's abnormal behavior, which causes the body to attack and destroy red blood cells at normal body temperatures. The main objective is to minimize or stop this immune-driven destruction, restore healthy red blood cell counts, and alleviate symptoms including fatigue, shortness of breath, and pallor.

The key treatment options for WAIHA include corticosteroids, monoclonal antibodies, intravenous immunoglobulin (IVIG), blood transfusions, and splenectomy. Corticosteroids are anti-inflammatory medications used to suppress the immune response and reduce inflammation. They can be administered orally, intravenously, or subcutaneously, and are suitable for children, adults, and older patients. These drugs are utilized for primary and secondary autoimmune disorders, as well as those related to genetic predisposition, and are available through hospital, retail, and online pharmacies.

The warm autoimmune hemolytic anemia (WAIHA) treatment market research report is one of a series of new reports from The Business Research Company that provides warm autoimmune hemolytic anemia (WAIHA) treatment market statistics, including warm autoimmune hemolytic anemia (WAIHA) treatment industry global market size, regional shares, competitors with a warm autoimmune hemolytic anemia (WAIHA) treatment market share, detailed warm autoimmune hemolytic anemia (WAIHA) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the warm autoimmune hemolytic anemia (WAIHA) treatment industry. This warm autoimmune hemolytic anemia (WAIHA) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The warm autoimmune hemolytic anemia (WAIHA) treatment market size has grown strongly in recent years. It will grow from $0.55 billion in 2024 to $0.60 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historical period can be linked to factors such as increased healthcare spending, a rise in clinical trials targeting rare hematologic conditions, expanding patient support and advocacy networks, and the growing elderly population.

The warm autoimmune hemolytic anemia (WAIHA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the rising prevalence of autoimmune disorders, enhanced awareness among healthcare professionals, the growing adoption of biologics and targeted therapies, and the increasing use of off-label drugs in treating autoimmune conditions. Key trends expected during this period include advancements in monoclonal antibody treatments, the integration of next-generation sequencing (NGS) in diagnostics, progress in immunology research, and the use of technology-driven drug discovery platforms.

The growing healthcare expenditure is expected to drive the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market in the coming years. Healthcare expenditure encompasses the total resources spent on health services, including prevention, diagnosis, treatment, and disease management, by individuals, governments, and organizations. Advancements in medical technology are contributing to increased healthcare spending, as the development, implementation, and ongoing care of newer diagnostic tools and treatments typically incur higher costs. Healthcare expenditure supports WAIHA treatment by funding research, facilitating access to advanced diagnostic tools, and ensuring the availability of specialized therapies that manage and control the disease. For example, in May 2024, the UK's Office for National Statistics reported that real-term health and social care expenditures grew by 2.8% in 2022, with overall healthcare spending rising by 5.6% in 2023. Thus, the rising healthcare expenditure is a key factor driving the growth of the WAIHA treatment market.

Innovations in monoclonal antibody therapies are driving progress in the treatment of warm autoimmune hemolytic anemia (WAIHA), with key companies in the market focused on developing cutting-edge solutions to meet unmet clinical needs and enhance patient outcomes. Monoclonal antibodies are laboratory-made proteins designed to target specific immune cells or pathways, aiming to reduce the destruction of red blood cells in WAIHA. For example, in July 2023, IASO Biotechnology, a biopharmaceutical company based in China, announced that the U.S. Food and Drug Administration (FDA) had approved IASO-782 Injection for clinical studies in autoimmune hematological conditions in the U.S., including WAIHA and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and incorporates Fc mutations to boost ADCC activity while preserving other Fc functions. It specifically depletes CD19+ B cells, plasma blasts, and certain plasma cells responsible for producing auto-reactive antibodies. With its unique mechanism, IASO-782 has potential for treating autoimmune disorders driven by pathogenic B and plasma cells, such as ITP and autoimmune hemolytic anemia (AIHA).

In September 2023, Zenas BioPharma Inc., a biotechnology company from the United States, partnered with Bristol Myers Squibb to develop and distribute the obexelimab antibody, a treatment for autoimmune diseases. This collaboration aims to create and bring to market effective new therapies for autoimmune disorders in key Asia-Pacific regions, addressing significant unmet medical needs and enhancing patient outcomes. Bristol Myers Squibb is a US-based pharmaceutical company, known for its expertise in treating warm autoimmune hemolytic anemia (WAIHA).

Major players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte corporation, Mallinckrodt Pharmaceuticals, Hutchison Medipharma Limited, BioCryst Pharmaceuticals Inc., Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., and Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in warm autoimmune hemolytic anemia (WAIHA) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the warm autoimmune hemolytic anemia (WAIHA) Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The warm autoimmune hemolytic anemia (WAIHA) treatment market consists of revenues earned by entities by providing services such as diagnostic testing services, immune system monitoring, personalized treatment planning and care coordination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The warm autoimmune hemolytic anemia (WAIHA) treatment market also includes sales of diagnostic kits, immunomodulatory agents, hematology analyzers and red blood cell monitoring tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on warm autoimmune hemolytic anemia (waiha) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for warm autoimmune hemolytic anemia (waiha) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The warm autoimmune hemolytic anemia (waiha) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Corticosteroids; Monoclonal Antibodies; Intravenous Immunoglobulin (IVIG); Blood Transfusions; Splenectomy
• 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 3) By Patient Demographics: Children; Adults; Geriatric
• 4) By Therapeutic Area: Primary Autoimmune Disorders; Secondary Autoimmune Disorders; Genetic Predisposition
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Corticosteroids: Prednisone; Dexamethasone; Methylprednisolone
• 2) By Monoclonal Antibodies: Rituximab; Sutimlimab; Bortezomib
• 3) By Intravenous Immunoglobulin: Standard IVIG; High-Dose IVIG Therapy; Pooled Plasma-Derived Immunoglobulins
• 4) By Blood Transfusions: Leukoreduced RBC Transfusions; Emergency Transfusions; Phenotypically Matched RBC Transfusions
• 5) By Splenectomy: Laparoscopic Splenectomy; Prophylactic Treatments Post-Splenectomy; Open Splenectomy
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Sanofi S.A.; AstraZeneca Plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Characteristics

3. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Trends And Strategies

4. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth Rate Analysis
• 5.4. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Total Addressable Market (TAM)

6. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Segmentation

• 6.1. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Monoclonal Antibodies
• Intravenous Immunoglobulin (IVIG)
• Blood Transfusions
• Splenectomy
• 6.2. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.3. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adults
• Geriatric
• 6.4. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Autoimmune Disorders
• Secondary Autoimmune Disorders
• Genetic Predisposition
• 6.5. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• Methylprednisolone
• 6.7. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab
• Sutimlimab
• Bortezomib
• 6.8. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Sub-Segmentation Of Intravenous Immunoglobulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard IVIG
• High-Dose IVIG Therapy
• Pooled Plasma-Derived Immunoglobulins
• 6.9. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Sub-Segmentation Of Blood Transfusions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukoreduced RBC Transfusions
• Emergency Transfusions
• Phenotypically Matched RBC Transfusions
• 6.10. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Sub-Segmentation Of Splenectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laparoscopic Splenectomy
• Prophylactic Treatments Post-Splenectomy
• Open Splenectomy

7. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Regional And Country Analysis

• 7.1. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 8.1. Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 9.1. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 9.2. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 10.1. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 11.1. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 11.2. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 12.1. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 13.1. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 14.1. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 14.2. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 15.1. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 15.2. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 16.1. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 17.1. Germany Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 18.1. France Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 19.1. Italy Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 20.1. Spain Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 21.1. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 21.2. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 22.1. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 23.1. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 23.2. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 24.1. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 24.2. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 25.1. Canada Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 25.2. Canada Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 26.1. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 26.2. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 27.1. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 28.1. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 28.2. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

• 29.1. Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
• 29.2. Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Competitive Landscape
• 30.2. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Agios Pharmaceuticals Inc.
• 31.4. Incyte corporation
• 31.5. Mallinckrodt Pharmaceuticals
• 31.6. Hutchison Medipharma Limited
• 31.7. BioCryst Pharmaceuticals Inc.
• 31.8. Xencor Inc.
• 31.9. Annexon Inc.
• 31.10. Rigel Pharmaceuticals Inc.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Momenta Pharmaceuticals Inc.
• 31.13. Immunovant Inc.
• 31.14. Zenas BioPharma Inc.
• 31.15. Alexion Pharmaceuticals Inc.

32. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

34. Recent Developments In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

35. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer